Ziccum AB (publ) confirms first day of trading on Spotlight to be Thursday 25 October 2018

23 October, 2018

STOCKHOLM, SWEDEN – 23 October, 2018. On Thursday 25 October 2018, trading begins in Ziccum AB’s shares and warrants of series TO 1 on Spotlight. The share will be traded under the designation ‘ZICC’, with ISIN code SE0011415595. Warrants of the series TO 1 will be traded under the trade designation ‘ZICC TO 1’, with ISIN code SE0011641950.

Issue oversubscribed before listing

The listing on Spotlight follows a share issue of units that raised 15.8 MSEK before issue costs for the company. The new issue was subscribed to approximately 52.7 MSEK including subscription commitments, which corresponds to a subscription ratio of approximately 334%. Following the issue the company has approximately 1000 shareholders.

Terms of warrants in brief

Holdings of two (2) warrants of series TO 1 entitle the holder to subscribe for (1) newly issued share at a price of 10.00 SEK. Subscription of shares on the basis of warrants may take place from 1 December 2019 until 31 December 2019.

Background

Ziccum was founded as a spin-out from Inhalation Sciences, which was successfully noted on Spotlight (formerly Aktietorget) in September 2017. Ziccum’s vision is to provide safe and effective drugs in all contexts and environments around the world, minimizing the need for costly and impractical cooler and freezer transport and storage.

Advisors

Fredersen Advokatbyrå AB has acted as legal adviser in connection with the issue. Aqurat Fondkommission AB has acted as the issuer.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.